Mebias Discovery

Mebias Discovery Initiates a Phase I Clinical Trial of MEB-1170, a Novel Analgesic Drug Candidate for the Treatment of Pain and Prevention of Opioid Use Disorder Preclinical Data Demonstrates MEB–1170 Lacks Adverse Effects of Opioids Including Respiratory Depression and Opioid Abuse Potential See more here

Mebias Discovery Receives Grant from NIDA to Advance MEB‑1170 as an Analgesic Drug Candidate for the Prevention and Treatment of Opioid Use Disorder  Grant to Fund IND Enabling and Phase 1 Clinical Trials Preclinical Data Demonstrates MEB‑1170 Lacks Dangerous Side Effects Including Respiratory Depression and Opioid Abuse Potential See more…

Mebias Discovery Raises $3.5 Million to Expand Pipeline Using a Novel, Cell Signaling-Pathway Selective GPCR Drug Discovery Platform Developing Programs to Focus on GI and Inflammation Therapies with Reduced, or No, Side Effects  See more here

Mebias Discovery Receives Grant from NIDA to Advance its Signaling-Pathway Selective MU-Opioid Receptor Drug Candidate Preclinical Studies of lead molecules have shown absence of respiratory depression, rewarding behavior, sedation, and constipation associated with traditional opioids     See more here

MEBIAS Discovery LLC Presents Pre-Clinical Data on MU Opioid Receptor Pain Compounds at ADDC  See more here